Ultragenyx Reduces Workforce and Closes Two Rare Disease Programs

Company Ultragenyx Event Type Restructuring and program discontinuation Modality Gene therapy; antisense oligonucleotide Asset UX701; GTX-102 Target ATP7B; UBE3A Disease Area Wilson disease; Angelman syndrome Summary Previously missed November 3 restructuring: Ultragenyx announced an approximately 20% workforce reduction, GTX-102 Angelman-study wind-down and termination of UX701…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *